Apolipoprotein E gene polymorphism is related to metabolic abnormalities, but does not influence erythrocyte membrane lipid composition or sodium-lithium countertransport activity in essential hypertension

• Published in: Metabolism, clinical and experimental clinical and experimental, 2001-02, Vol.50 (2), p.157-160
• Main Authors: Stiefel, P., Montilla, C., Muñiz-Grijalvo, O., Garcı́a-Lozano, R., Alonso, A., Miranda, M.L., Pamies, E., Villar, J.
• Format: Article
• Language: English
• Subjects: Adult; Antiporters - metabolism; Apolipoprotein E4; Apolipoproteins E - genetics; Arterial hypertension. Arterial hypotension; Biological and medical sciences; Blood and lymphatic vessels; Blood Glucose; Blood Pressure; Body Mass Index; Cardiology. Vascular system; Cholesterol - analysis; Cholesterol - blood; Clinical manifestations. Epidemiology. Investigative techniques. Etiology; Erythrocyte Membrane - chemistry; Erythrocyte Membrane - metabolism; Female; Gene Frequency; Genotype; Humans; Hypertension - blood; Hypertension - genetics; Hypertension - metabolism; Insulin - blood; Insulin Resistance; Lithium - metabolism; Male; Medical sciences; Membrane Lipids - analysis; Middle Aged; Phospholipids - analysis; Polymorphism, Genetic; Sodium - metabolism; Triglycerides - blood
• ISSN: 0026-0495; 1532-8600
• DOI: 10.1053/meta.2001.19429

The aim of this study was to analyze the influence of the apolipoprotein E (apoE) gene polymorphism on insulin resistance and plasma lipid composition of essential hypertensive patients. A secondary objective was to analyze if differences regarding plasma lipids had an effect on the erythrocyte membrane lipid composition and the activity of the erythrocyte membrane sodium-lithium countertransport. We studied 128 untreated nondiabetic essential hypertensive patients enrolled from our outpatient clinic. We considered as hyperinsulinemic all subjects having more than 80 mU/L of plasma insulin 120 minutes after a 75-g oral glucose intake. The number of hyperinsulinemic subjects among carriers of the ϵ4 allele was higher that in ϵ4 noncarrier subjects (13 of 19 v 45 of 109, P < .05; odds ratio [OR], 3.08; confidence interval [CI], 0.99-10.57). Plasma insulin at baseline and plasma insulin and glucose at 120 minutes after overload was higher in carriers of the ϵ4 allele (respectively, 17.5 ± 6.9 v 12.4 ± 4.9 mU/L, P < .01; 111.9 ± 39.9 v 88.7 ± 48.2, P < .05; and 143.8 ± 29.3 v 121.2 ± 30.8 mg/dL, P < .005). Subjects with the ϵ4 allele had a plasma lipid profile more atherogenic than those without this allele. This profile was mainly characterized by higher levels of low-density lipoprotein (LDL) cholesterol (150.1 ± 31.2 v 133.0 ± 34.3 mg/dL, P < .05) and very-low-density lipoprotein (VLDL) triglycerides (134.7 ± 85.5 v 99.2 ± 68.8 mg/dL, P < .05) and by lower levels of high-density lipoprotein (HDL) cholesterol (41.8 ± 10.7 v 50.0 ± 14.7 mg/dL, P < .05). There were no differences between groups regarding erythrocyte membrane cholesterol or phospholipids composition and sodium-lithium countertransport (SLC) activity.